Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03597529 · ClinicalTrials.gov registry record · Phase 2
CHOCOlate MeLatonin for AdolescenT MigrainE
A Phase 2 study of Migraine, sponsored by Amy Gelfand.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT03597529: Completed Phase 2 study of Migraine, sponsored by Amy Gelfand.
NCT03597529 is a Phase 2 study of Migraine that has completed, run by Amy Gelfand. The registered enrollment target is 84 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03597529, a Phase 2 study of Migraine, has completed, sponsored by Amy Gelfand.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
Existing treatments for acute migraine are not effective for all children and adolescents, and can cause side effects. Investigator propose a dose-finding study of melatonin for acute migraine treatment in children and adolescents to determine the best dose to bring forward in a future fully-powered efficacy trial.
Primary Outcome
Visual Analog Scale (VAS) score ranges from 0-10, measured in cm, 0 indicating no pain and 10 indicating the worst pain.
Conditions Studied
Interventions
- DRUG Melatonin
Study Locations (1)
California
- University of California, San Francisco, (UCSF) - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2019-12-01 |
| Phase | Phase 2 |
What the finished NCT03597529 record still lists
NCT03597529 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Melatonin is the first listed.
NCT03597529 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03597529 about?
NCT03597529 is a clinical study titled "CHOCOlate MeLatonin for AdolescenT MigrainE". Existing treatments for acute migraine are not effective for all children and adolescents, and can cause side effects. Investigator propose a dose-finding study of melatonin for acute migraine treatment in children and adolescents to determine the best dose to bring forward in a future fully-powered...
What is the current status of trial NCT03597529?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2017-09-25. Estimated completion is 2019-12-01.
What conditions does trial NCT03597529 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT03597529?
The interventions under investigation include: Melatonin (DRUG).
Who is sponsoring clinical trial NCT03597529?
This trial is sponsored by Amy Gelfand, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03597529 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03597529's enrollment target sits among peer trials
84 64th of 102 higher than 38 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
RECRUITING · Phase 2
-
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
RECRUITING · Phase 2
-
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI